Other high-risk subtypes such as hypodiploid ALL, early T-cell precursors, immature T-cells, KMT2A rearranged, Ph-positive, and TCF::HLF-positive ALL may benefit from treatment with the BCL-2 inhibitor venetoclax. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.